The apolipoprotein AII rs5082 variant is associated with reduced risk of coronary artery disease in an Australian male population

Atherosclerosis. 2008 Aug;199(2):333-9. doi: 10.1016/j.atherosclerosis.2007.11.017. Epub 2008 Jan 7.

Abstract

Serum high density lipoprotein (HDL) levels are inversely related to the development of coronary artery disease (CAD). Apolipoproteins AI and AII are the major protein constituents of HDL particles. APOAI and APOAII genetic polymorphisms have been proposed to affect transcriptional efficiency of their respective genes, thereby altering serum lipid levels and influencing atherosclerotic disease risk. 556 subjects with angiographically proven CAD (>50% stenosis) and 1109 randomly selected individuals from metropolitan Perth, Western Australia, were included in an association study. APOAI -75G/A (rs670) and APOAII -256T/C (rs5082) polymorphisms were both found to be not associated with plasma HDL levels. In a case-control analysis of 484 male CAD patients and 498 male controls, individuals carrying the 'CC' genotype for the APOAII rs5082 polymorphism had significantly lower risk of CAD than the 'T' allele carriers (OR=0.57, 95% CI 0.39-0.84, p=0.004). The minor 'A' allele of the APOAI rs670 polymorphism was found to be not associated with CAD, contrary to previous reports. We conclude that the APOAII rs5082 polymorphism appears to be cardioprotective in this representative Caucasian Australian population.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Apolipoprotein A-II / genetics*
  • Australia
  • Carotid Arteries / diagnostic imaging
  • Carotid Arteries / pathology
  • Case-Control Studies
  • Coronary Artery Disease / genetics*
  • Genetic Predisposition to Disease
  • Genetic Variation
  • Genotype
  • Humans
  • Lipids / chemistry
  • Male
  • Middle Aged
  • Polymorphism, Genetic
  • Risk
  • Ultrasonography

Substances

  • Apolipoprotein A-II
  • Lipids